Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 14;17(1):214.
doi: 10.1186/s13098-025-01790-w.

Dual-faced guardians: SGLT2 inhibitors' kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)

Amin Roshdy Soliman  1 , Mohamed Elkhatib  1 , Sahier El-Khashab  1 , Rasha Ahmed Darwish  1 , Ahmed Fayed  1 , Tarek S Abdelaziz  1 , Hany Hammad  1 , Rabab Mahmoud Ahmed  1 , Hoda Abdelhamid Maamoun  2
Affiliations
Review

Dual-faced guardians: SGLT2 inhibitors' kidney protection and health challenges: a position statement by Kasralainy nephrology group (KANG)

Amin Roshdy Soliman et al. Diabetol Metab Syndr. .

Abstract

Background: SGLT2 inhibitors represent a revolutionary drug class that delivers benefits exceeding those of diabetes management alone. Initially approved for type 2 diabetes management, research continually demonstrates their protective effects on kidney function across several nephrological conditions, including acute kidney injury (AKI), chronic kidney disease (CKD), dialysis-dependent kidney failure, anemia, metabolic bone disease, polycystic kidney disease (PKD), glomerulonephritis, and kidney transplantation.

Purpose: This study aims to identify how SGLT2 inhibitors modify nephrological care by investigating their mechanisms of action, therapeutic outcomes, and potential applications in multiple kidney diseases. It summarizes clinical trial data alongside mechanistic insights to provide a comprehensive assessment of therapeutic outcomes beyond diabetes mellitus.

Findings: Numerous clinical studies have demonstrated that SGLT2 inhibitors reduce kidney disease progression in patients with or without diabetes. These findings indicate that SGLT2 inhibitors provide kidney protection by enhancing tubuloglomerular feedback, improving renal blood flow, and reducing inflammation and ischemic tissue damage. They also provide cardiovascular benefits to dialysis patients while maintaining effective blood flow during dialysis. SGLT2 inhibitors should not be used in autosomal dominant polycystic kidney disease (ADPKD) outside clinical trials. The potential impact of SGLT2 inhibitors on bone mineral health, particularly regarding bone mineral density (BMD) reduction and fracture risk, requires careful consideration, especially in patients with pre-existing bone health concerns. Kidney transplant recipients benefit from SGLT2 inhibitors' protective effects on kidney health and assistance with diabetes management; however, further research is needed on drug compatibility with immunosuppressants and infection prevention.

Keywords: Kidney disease management; Renoprotection; SGLT2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
SGLT2 Inhibitors’ Kidney Protection and Health Challenges
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Packer M, Wilcox CS, Testani JM. Critical analysis of the effects of SGLT2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes. Circulation. 2023;148(4). 10.1161/CIRCULATIONAHA.123.0643. - PMC - PubMed
    1. Zhou Y, Li C, Li H. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. J Diabetes Complicat. 2018;32(7):720–5. 10.1016/j.jdiacomp.2018.03.008. - PubMed
    1. Mima A. Sodium-Glucose cotransporter 2 inhibitors in patients with Non-Diabetic chronic kidney disease. Adv Therapy. 2021;38(5):2201–12. 10.1007/s12325-021-01735-5. - PubMed
    1. Mima A. Mitochondria-targeted drugs for diabetic kidney disease. Heliyon. 2022;8(2):e08878. 10.1016/j.heliyon.2022.e08878. - PMC - PubMed
    1. Koh ES, Kim G-H, Chung S. Intrarenal mechanisms of sodium-glucose cotransporter-2 inhibitors on tubuloglomerular feedback and natriuresis. Endocrinol Metabolism. 2023;38(4):359–72. 10.3803/EnM.2023.1764. - PMC - PubMed

LinkOut - more resources